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Angiogenesis is a necessary component of solid tumour growth
(Folkman, 1990). It allows delivery of oxygen and nutrients to the
tumour, and facilitates the transport of tumour cells to distant sites.
In addition, secretion of certain cytokines and growth factors by
the newly formed endothelial cells can have a paracrine effect on
tumour growth by directly stimulating the tumour cells (Rak,
1996). The rate of angiogenesis is controlled by a number of
factors secreted by the tumour cells. VEGF has been identified as
one of the most important of these factors.
VEGF was initially detected as a factor, secreted by tumour
cells into tissue culture medium or ascitic fluid, that caused normal
blood vessels to become hyperpermeable (Senger et al, 1983).
Subsequently it has been shown to be over-expressed in a number
of human tumours, as well as in healing wounds, rheumatoid
arthritis and delayed hypersensitivity reactions. It is a homod-
imeric heparin-binding glycoprotein that exists in 5 isoforms (121,
145, 165, 189 and 206).
VEGF plays a critical role in tumour angiogenesis by increasing
blood vessel permeability, and endothelial cell growth, prolifera-
tion, migration and differentiation (Ferrara, 1995). It may also
facilitate extravasation of tumour cells and thereby the formation
of metastases by degrading the tumour marginal extracellular
matrix via activation of proteolytic enzymes (Pepper et al, 1991).
VEGF is one of a group of ‘survival genes’ whose expression is
up-regulated in response to hypoxia via the transcription factor
HIF-1 which exists as a functional stable dimer only in low
oxygen tensions. In addition to HIF-1, a number of other cytokines
can up-regulate VEGF, including known angiogenic growth
factors such as bFGF, TGFα and epidermal growth factor. Mutant
p53 and mutant ras have also been shown to up-regulate and
enhance hypoxia-induced VEGF (Keiser et al, 1994; Rak et al,
1995) whereas wild type p53 has been shown to down-regulate
VEGF transcription (Bouvet et al, 1998).
The receptors for VEGF are tyrosine kinases (VEGFR1 and
VEGFR2) that are expressed predominantly on endothelial cells, but
have also been identified on tumour cells (Boocock et al, 1995). This
raises the possibility that VEGF may act not only as an angiogenic
and vasopermeability factor, but also as a tumour cell autocrine factor.
High tumour expression of VEGF protein has been linked to
poor outcome in a number of human tumour sites including
stomach (Maeda et al, 1996), ovary (Paley et al, 1997; Yamamoto
et al, 1997), oesophagus (Inoue et al, 1997; Uchida et al, 1998),
breast (Linderholm et al, 1998), colorectum (Ishigami et al, 1998),
lung (Fontanini et al, 1999) and bone (Lee et al, 1999). Although
there is ample evidence that VEGF contributes to microinvasion in
early stage disease (Guidi et al, 1995; Obermair et al, 1997), no
large studies have examined the prognostic significance of VEGF
expression in locally advanced carcinoma of the cervix. There is
one small study that reported VEGF expression to have no predic-
tive power in surgically treated disease (Hawighorst et al, 1998).
As radiotherapy is the treatment of choice in locally advanced
carcinoma of the cervix, we have examined the relationship
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doi: 10.1054/ bjoc.2000.1319, available online at http://www.idealibrary.com on between VEGF expression and radiotherapy outcome in cervical
carcinoma, and assessed its independence as a prognostic factor
using multivariate analysis.
MATERIALS AND METHODS
Patients
A total of 100 patients with locally advanced (i.e., bulky stage Ib
to IIIb) carcinoma of the cervix were included in the study. All the
patients gave prior written consent to allow tumour biopsies to be
taken for research purposes at the time of their examinatiosn
under anaesthesia (EUA). An EUA was undertaken on all patients
in order to establish staging according to FIGO criteria. Of the
100 patients, 94 had squamous cell carcinoma, 5 had adenocarci-
noma and one had adenosquamous carcinoma. All patients were
treated with radiotherapy with curative intent according to the
standard techniques of the Manchester school (West et al, 1993).
Patients were reviewed in specialist oncology clinics, following a
standard protocol, for a minimum of five years. Further follow up
information was obtained from questionnaires to general practi-
tioners. The median follow-up time was 49 months (range 3–117
months). For surviving patients, the median follow-up was 80
months (range 28–117 months). The sites of any disease relapse
were identified clinically and radiologically, and where appro-
priate was confirmed on biopsy. The recurrences were then classi-
fied as being either local (i.e. within the radiotherapy field) or
metastatic (i.e. outside the radiotherapy field). Pelvic side-wall
recurrence was taken as local for tumours that had received
external beam radiotherapy or as metastatic for tumours treated
by intracavity radiotherapy alone. Data were also available for
tumour radiosensitivity, measured as the surviving fraction at 2
Gy (SF2) on 62 patients from previous work by the group (West et
al, 1993).
Assessment of tumour VEGF protein expression
Measurements were made on pre-treatment biopsy material.
Formalin-fixed, paraffin-embedded, 4-µ m sections were pre-
pared from the biopsy specimens, and were immunostained using
a Dako envision™+ system. Following deparaffination and
rehydration, antigen retrieval was performed by microwaving for
25 minutes in Tris-HCl 0.05M, pH 8.5, containing EDTA
0.001M. After resting for 15 minutes an endogenous peroxidase
block, supplied with the kit, was applied for 5 minutes.
Following washing, the samples were incubated with 10% casein
(Vector) in TBS (blocking buffer) for 10 minutes. Sections were
then incubated for 30 minutes at room temperature with anti-
VEGF polyclonal antibody (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) at 1 in 200 dilution. The antibody was chosen
for a number of reasons. First, it is widely available and used in
clinical studies (e.g., Kuhnen et al, 2000; Parliament et al, 2000).
Second, it was used in several studies and shown to have prog-
nostic significance (Maeda et al, 1996; Yamamoto et al, 1997).
Third, others have confirmed the reliability of the antibody and
shown it to be highly specific in immunohistochemical reactions
of human tumours (Ohta et al, 1996; Takahashi et al, 1996;
Itakura et al, 1997).
A solution of normal rabbit immunoglobulin was diluted to the
same concentration and substituted for the primary antibody to act
as a negative control. Following washing, the sections were
incubated at room temperature for 30 minutes with a peroxidase
labelled polymer conjugated to goat-anti-rabbit immunoglobulins
in Tris-HCl buffer (supplied in the kit). A substrate-chromogen
solution containing 3,3′ -diaminobenzidine in a buffered substrate
solution (pH 7.5) containing hydrogen peroxide, again supplied
with the kit, was applied for 5 minutes. After rinsing in water, the
slides were lightly counter-stained with Gills haematoxylin,
dehydrated and mounted.
The VEGF expression in the tumour cells was evaluated using 
a semi-quantitative scoring system: 0 for absence of immuno-
staining, 1 for light staining, 2 for moderate staining, and 3 for
heavy staining. Any staining of the tumour stroma was ignored in
this assessment. Batch to batch variation was excluded by running
sections from the same biopsy through more than one batch, and
running one biopsy section through all the batches.
Statistical analysis
Survival was analysed using the Kaplan-Meier method, and prog-
nostic factors were assessed by log-rank analysis. Univariate and
bivariate analyses were made of overall survival, metastasis-free
survival, and local recurrence-free survival. Patients were strati-
fied by their VEGF score as well as other putative prognostic
factors (age, stage, tumour differentiation and SF2). A stepwise
multivariate Cox regression analysis was also performed to further
test the independence of VEGF from other parameters. The
distribution of the VEGF score in relation to the tumour and
patient characteristics was investigated using Fisher’s exact test.
Correlations between variables were obtained using Spearman’s
rank correlation.
RESULTS
Scoring reproducibility
Intra-observer variation for scoring of VEGF intensity was tested
on a random sample of 33 slides, scored by the same observer
(JAL) at least one month after the initial scoring. The results corre-
lated significantly (r = 0.80, P < 0.001). Where the score differed
from the initial score, it did so only by one scale point. Inter-
observer variability was assessed by a different observer (CMLW)
re-scoring 20 of the slides. There was a significant correlation
between the two observers’ scores (r = 0.93, P < 0.001). Again,
when any differences in scores were identified, they varied by only
one scale point.
Batch to batch variation was assessed by scoring sections from
the same biopsies that had been run through more than one batch.
Out of fifteen repeat sections, the score varied by one scale point in
one section only. The other 14 sections were scored identically,
independent of batch.
VEGF expression
Immunostaining was essentially cytoplasmic but occasionally seen
in the nuclei. It was located primarily in the tumour cells, although
weaker staining was seen in the stroma of most sections. There
was no obvious spatial relationship to the tumour blood vessels. In
most cases where positive staining was identified, the intensity
remained fairly homogeneous thoughout the tumour section.
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the sections.
Distribution of patients according to VEGF intensity
Table 1 summarises the distribution of the 100 patients according
to tumour VEGF intensity and various clinical and biological char-
acteristics. Using Fisher’s exact test no significant differences
were seen in the distribution of patients according to VEGF
expression and any of the characteristics studied. Using
Spearman’s rank analysis there was also no significant correlation
between VEGF score and patient age (r = 0.12, P = 0.23), disease
stage (r = 0.57, P = 0.55) or SF2 (r = 0.15, P = 0.24).
Correlation with outcome
Tumour VEGF expression was a highly significant prognostic
factor for survival (Figure 1) and metastasis-free survival
(Figure 2), but not for local control (Figure 3). In univariate
log-rank analysis only VEGF expression and radiosensitivity
were predictive of treatment outcome (Table 2). Bivariate log-
rank analyses were carried out in order to test the independence
of VEGF expression from other potential prognostic factors.
After allowing for patient age, tumour stage, differentiation,
and SF2, the level of VEGF expression remained a significant
prognostic factor for both overall and metastasis-free survival
(Table 3).
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Table 1 Summary of the distribution of patients according to VEGF intensity
Parameter n VEGF 0 VEGF 1 VEGF 2 VEGF 3 P a
Stage I 35 1 12 10 12
II 36 4 8 14 10
III 29 1 7 12 9 0.52
Age < 49 years 53 4 17 18 14
> 49 years 47 2 10 18 17 0.61
Histology SCCb 94 4 25 35 30
Adenocarcinoma 5 2 2 0 1
Adenosquamous 1 0 0 1 0 0.10
Differentiation Well 16 2 7 4 3
Moderate 62 4 14 24 20
Poor 22 0 6 8 8 0.29
Radiosensitivity SF2 < median 35 3 8 15 9
SF2 > median 27 0 5 9 13 0.24
aFisher’s exact test for differences in the distribution of patients according to the parameters listed; bsquamous cell carcinoma
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Figure 1 Overall survival in relation to VEGF expression for 100 cervical
cancer patients treated with radiotherapy with a median follow-up for
surviving patients of 80 months. Patients were stratified according to the
intensity of VEGF expression. The numbers of disease-related deaths and
patients in each arm are indicated
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Figure 2 Metastasis-free survival in relation to VEGF expression for 100
cervical cancer patients treated with radiotherapy with a median follow-up for
surviving patients of 80 months. Patients were stratified according to the
intensity of VEGF expression. The numbers of events and patients in each
arm are indicatedA Cox multiple regression analysis was performed to further
evaluate the independence of VEGF expression as a prognostic
factor (Table 4). The level of VEGF expression emerged as the most
important prognostic indicator for overall survival. After allowing
for VEGF intensity only SF2 was an independent prognostic factor
for overall survival. VEGF expression and SF2 were also significant
independent predictors for metastasis-free survival. Only SF2 was
an independent prognostic factor for local recurrence.
DISCUSSION
VEGF as a prognostic factor
This study illustrates the importance of tumour VEGF expression
as a significant and independent prognostic factor in cervical
carcinoma. The work supports the findings of other groups looking
at different tumour sites and involving treatment predominantly by
surgery (Maeda et al, 1996; Paley et al, 1997; Yamamoto et al,
1997; Inoue et al, 1997; Ishigami et al, 1998; Linderholm et al,
1998; Uchida et al, 1998; Fontanini et al, 1999; Lee et al, 1999).
VEGF expression was significantly associated with both overall
and metastasis-free survival but not local control. This suggests
that VEGF expression is primarily reflecting the metastatic poten-
tial of a tumour rather than response to radiotherapy. The latter
suggestion is supported by the known roles of VEGF in promoting
metastatic spread by increasing blood vessel permeability and
establishing a new blood supply required for tumour growth
(Ferrara, 1995). It is also supported by the proposed role of VEGF
in the induction of the plasminogen activation system (Pepper et
al, 1991), which would increase the metastatic potential of the
tumour via degradation of the marginal extracellular matrix.
Previous work by us demonstrated intrinsic radiosensitivity
(SF2) to be a strong predictor of outcome following radiotherapy
for cervical carcinoma (West et al, 1993). This study has shown
that SF2 remains the strongest predictor of local control but that
VEGF expression is the strongest predictor of overall survival and
is entirely independent of SF2.
We have shown that the method of assessing VEGF expression
is highly reproducible. There is minimal inter-batch variation and
good correlation between inter- and intra-observer scores. The
method is rapid and results can be available within days of taking
the biopsy. It could be easily incorporated into routine clinical
practice, at a time when treatment decisions are being made.
Potential applications for assessing tumour VEGF
expression
Patients with a high intensity of tumour VEGF expression have
been shown to have a particularly poor prognosis. This informa-
tion may be used in future to individualize treatment. There are a
number of potential approaches. First, patients with high VEGF
expression could be offered concurrent chemotherapy. Patients
with locally advanced cervical carcinomas presently receive
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Figure 3 Local control in relation to VEGF expression for 100 cervical
cancer patients treated with radiotherapy with a median follow-up for
surviving patients of 80 months. Patients were stratified according to the
intensity of VEGF expression. The numbers of events and patients in each
arm are indicated
Table 2 Univariate log-rank analysis of putative prognostic factors for outcome following radical radiotherapy
for carcinoma of the cervix. The P values for each factor are given
Parameter n Overall survival Metastasis-free Local control
survival
Stage 100 0.17 0.29 0.20
Differentiation 100 0.27 0.51 0.92
Age 100 0.85 0.19 0.71
SF2a 62 < 0.001 0.002 0.003
VEGF intensity 100 0.0008 0.0062 0.23
aSurviving fraction at 2 Gy
Table 3 Bivariate stratified log-rank analyses showing the significance of VEGF expression as a
prognostic factor for cervical carcinoma after allowing for the listed parameters
Parameter n Overall survival Metastasis-free survival Local control
PP P
Stage 100 0.004 0.020 0.30
Differentiation 100 0.005 0.055 0.36
Age 100 0.005 0.017 0.26
SF2a 62 0.005 0.023 0.24
aSurviving fraction at 2 Gyradical radiotherapy as the standard treatment. However in the
light of recent reports of improved survival for patients treated
with concurrent cisplatin-containing chemoradiotherapy (Keys et
al, 1999; Morris et al, 1999; Peters et al, 1999; Rose et al, 1999;
Whitney et al, 1999) many clinicians have been encouraged to
adopt this as their standard approach. As yet there is little informa-
tion on the late toxicity following this combined treatment. The
patients in this study with low tumour expression of VEGF have
been shown to have a good overall survival rate, and therefore may
be less likely to benefit from concurrent chemotherapy and its
potential additional toxicities. VEGF expression could be used to
guide the use of concurrent chemotherapy and allow the selection
of patients with good prognosis tumours who could be treated with
radiotherapy alone. Second, it has been shown that prolonged
exposure to hypoxia can induce VEGF mRNA in cervical cell
lines (Chiarotto and Hill, 1999), although this relationship has not
been demonstrated in vivo in solid tumours (Raleigh et al, 1998).
If VEGF production is directly linked to hypoxia in solid tumours
then it is possible that hypoxic cell modification may reduce
VEGF expression. Third, analysis of VEGF expression could indi-
cate the patients most likely to benefit from therapy targeting
VEGF-mediated tumour angiogenesis. Anti-VEGF antibodies
have the ability to inhibit the growth of several tumour cell lines in
nude mice (Kim et al, 1993; Warren et al, 1995) and can inhibit
ascites formation in mice transplanted with ascites-producing
tumours (Nagy et al, 1995). The safety and efficacy of this strategy
is presently being tested in humans (Presta et al, 1997). Fourth, the
use of retroviruses encoding dominant-negative mutant VEGF
receptors can block the effects of VEGF and retard tumour growth
(Millaeur et al, 1994). Finally, gene therapy involving the replace-
ment of mutant p53 by restoration of wt p53 can down-regulate
VEGF expression and thereby inhibit angiogenesis (Bouvet et al,
1998).
In conclusion, tumour expression of VEGF as assessed by
immunohistochemical analysis is a highly significant and indepen-
dent prognostic factor for patients with carcinoma of the cervix
treated with radiotherapy. The method used is quick, simple and
reproducible, and could be used to aid treatment stratification and
direct the use of anti-angiogenic therapies.
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